The SGLT2 inhibitor ertugliflozin causes a switch of cardiac substrate utilization leading to reduced cardiac mTOR-signaling, unfolded protein response and apoptosis

Authors: J Moellmann, P Mann, K Krueger, B Klinkhammer, P Boor, N Marx, M Lehrke

Published: 2021-10-20

DOI: 10.1093/eurheartj/ehab724.3289

Source: Full article